Anzeige
Mehr »
Dienstag, 10.02.2026 - Börsentäglich über 12.000 News
Breaking News: Pacifica meldet neue hochgradige Entdeckung und genau deshalb kann der Markt das nicht ignorieren
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
405 Leser
Artikel bewerten:
(1)

Informa Business Intelligence: Informa Pharma Intelligence launches Preferred Partner Network to provide enhanced specialist support for customers' content and technology needs

NEW YORK, Nov. 17, 2021, the global business intelligence provider for the biopharma industry, announced the launch of its Preferred Partner Network to enhance the services supplied to customers across the drug development lifecycle.

Built on Informa Pharma's deep industry expertise and years of collaborating with like-minded companies, the network will bring together hand-picked industry specialists to create a select ecosystem of best-in-class services providers. The inaugural members of the Preferred Partner Network are Blueprint Advisory, Causaly, and ROSALIND, each bringing their unique strengths in the drug development and clinical trial process.

The network will seamlessly integrate Informa Pharma's gold-standard content with Preferred Partners' technology and services solutions to further support decision-makers in the pharma industry. This partnership will also provide a space for growing companies to work closely with other leading content and technology providers, as well as connect with life science and healthcare communities to increase efficiency in drug development.

"By launching the Preferred Partner Network, we can take our support for customers to the next level," said Nicky Marlin, Chief Product and Technology Officer at Informa Pharma Intelligence. "Individually, each partner provides essential technologies and services for the pharmaceutical industry, but together, we can significantly strengthen and streamline our positive contribution to the drug development landscape as a whole. We are proud to have Blueprint Advisory, Causaly, and ROSALIND join us as key partners in this endeavor."

All Preferred Partners are endorsed by Informa as gold-standard vendors for integration with Informa Pharma's content, and each partner receives individualized technical support on relevant customer projects and prioritization through Informa's Third Party Access (TPA) Program. This includes dedicated, tailored success plans to ensure that each member achieves its goals, with the ultimate goal to deliver leading combined offerings to support mutual clients.

Blueprint Advisory

Blueprint Advisory is a Salesforce Consulting Partner with a successful track record of implementing Informa Pharma Intelligence's APIs. Blueprint Advisory supports Informa customers' business development and data teams throughout the discovery, implementation, and enhancement process to ensure that customers can extract value in ways that are truly impactful to their business.

Causaly

Causaly accelerates how humans acquire knowledge and develop insights in biomedicine. Causaly helps researchers and decision-makers discover evidence from millions of academic publications, clinical trials, regulatory documents, patents, and other data sources.

ROSALIND

ROSALIND is the first genomics discovery and collaboration platform specifically designed for scientists and biologists. ROSALIND aims to simplify the practice of genomic data interpretation, so that biologists, researchers, and drug developers can harness the potential of genomic information while reducing costs and increasing productivity.

For more information about the Preferred Partner Network, email IPIthirdpartyaccess@informa.comor visit Informa Pharma Intelligence.

About Informa Pharma Intelligence

Informa Pharma Intelligence powers a full suite of analysis products - Datamonitor Healthcare, Sitetrove, Trialtrove, Pharmaprojects, Biomedtracker, Scrip, Pink Sheet and In Vivo - to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth.

With more than 400 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isn't covered through the breadth and depth of data available to customers. For more information, visit pharmaintelligence.informa.com.

Informa Pharma Intelligence PR Contact
Diffusion PR for Informa Pharma Intelligence
informapharma@diffusionpr.com


© 2021 GlobeNewswire (Europe)
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.